Eben Tessari Biography and Net Worth

https://monarchcasino.com/corporategovernance_boardofdirectors.asp of Kiniksa Pharmaceuticals International

Eben joined Kiniksa as it was founded in 2015. He was initially Chief Business Officer where he oversaw long-range strategic planning, forecasting, decision analysis, business development, licensing, valuation, and new product strategy. In January 2022, Eben was promoted to Chief Operating Officer where he oversees our functional leadership teams in business development, program management, clinical development, manufacturing, and research. Before Kiniksa, he was Senior Director and Head of Business Development at Synageva BioPharma. Prior to that he was Director, Business and Corporate Development for Civitas Therapeutics. There he played a lead role in managing the company through a dual-path IPO process which led, ultimately, to a successful acquisition by Acorda Therapeutics. Before joining Civitas, he worked in a variety of roles with increasing responsibility at Vertex Pharmaceuticals, Zalicus, and EPIX Pharmaceuticals. Eben holds a BS in behavior neuroscience from Northeastern, an MS in biomedical engineering from Boston University and both a JD and MBA from Suffolk University.

What is Eben Tessari's net worth?: The estimated net worth of Eben Tessari is at least $931.05 thousand as of November 26th, 2025. Mr. Tessari owns 22,714 shares of Kiniksa Pharmaceuticals International stock worth more than $931,047 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Tessari may own. Additionally, Mr. Tessari receives an annual salary of $733,290.00 as https://monarchcasino.com/corporategovernance_boardofdirectors.asp at Kiniksa Pharmaceuticals International. Learn More about Eben Tessari's net worth.
How old is Eben Tessari?: Mr. Tessari is currently 42 years old. There are 5 older executives and no younger executives at Kiniksa Pharmaceuticals International. The oldest executive at Kiniksa Pharmaceuticals International is Dr. John F. Paolini FACC, M.D., Ph.D., Senior VP & Chief Medical Officer, who is 59 years old. Learn More on Eben Tessari's age.
What is Eben Tessari's salary?: As the https://monarchcasino.com/corporategovernance_boardofdirectors.asp of Kiniksa Pharmaceuticals International, plc, Mr. Tessari earns $733,290.00 per year. There are 2 executives that earn more than Mr. Tessari. The highest earning executive at Kiniksa Pharmaceuticals International is Mr. Sanj K. Patel, CEO & Chairman of the Board, who commands a salary of $1,570,000.00 per year. Learn More on Eben Tessari's salary.
How do I contact Eben Tessari?: The corporate mailing address for Mr. Tessari and other Kiniksa Pharmaceuticals International executives is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. Kiniksa Pharmaceuticals International can also be reached via phone at (781) 431-9100 and via email at [email protected]. Learn More on Eben Tessari's contact information.
Has Eben Tessari been buying or selling shares of Kiniksa Pharmaceuticals International?: During the last ninety days, Eben Tessari has sold $988,743.36 in shares of Kiniksa Pharmaceuticals International stock. Most recently, Eben Tessari sold 200 shares of the business's stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $42.89, for a transaction totalling $8,578.00. Following the completion of the sale, the chief operating officer now directly owns 22,714 shares of the company's stock, valued at $974,203.46. Learn More on Eben Tessari's trading history.
Who are Kiniksa Pharmaceuticals International's active insiders?: Kiniksa Pharmaceuticals International's insider roster includes Thomas Malley (Director), Michael Megna (Group Vice President of Finance and Chief Accounting Officer), Ross Moat (Executive Vice President, Chief Commercial Officer), John Paolini (Executive Vice President, Chief Medical Officer), Sanj Patel (CEO and Chairman of the Board), Barry Quart (Director), Mark Ragosa (CFO), and Eben Tessari (https://monarchcasino.com/corporategovernance_boardofdirectors.asp). Learn More on Kiniksa Pharmaceuticals International's active insiders.
Are insiders buying or selling shares of Kiniksa Pharmaceuticals International?: In the last year, insiders at the sold shares 57 times. They sold a total of 1,575,162 shares worth more than $51,430,265.98. The most recent insider tranaction occured on November, 26th when COO Eben Tessari sold 200 shares worth more than $8,578.00. Insiders at Kiniksa Pharmaceuticals International own 53.5% of the company. Learn More about insider trades at Kiniksa Pharmaceuticals International.
Information on this page was last updated on 11/26/2025.

Eben Tessari Insider Trading History at Kiniksa Pharmaceuticals International

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/26/2025	Sell	200	$42.89	$8,578.00	22,714
11/17/2025	Sell	12,470	$41.24	$514,262.80	22,714
10/14/2025	Sell	12,368	$37.67	$465,902.56	28,684
9/29/2025	Sell	42,000	$38.33	$1,609,860.00	34,552
9/15/2025	Sell	16,400	$36.46	$597,944.00	34,552
9/5/2025	Sell	13,389	$35.66	$477,451.74	44,452
9/4/2025	Sell	85,271	$35.52	$3,028,825.92	44,452
9/3/2025	Sell	15,091	$35.50	$535,730.50	44,452
8/18/2025	Sell	16,200	$33.77	$547,074.00	40,215
8/5/2025	Sell	138,614	$33.20	$4,601,984.80	49,915
7/14/2025	Sell	18,900	$28.72	$542,808.00	49,163
6/16/2025	Sell	17,300	$28.28	$489,244.00	61,563
6/11/2025	Sell	45,042	$30.51	$1,374,231.42	72,363
6/10/2025	Sell	15,506	$30.46	$472,312.76	72,363
6/9/2025	Sell	10,319	$30.38	$313,491.22	72,363
5/19/2025	Sell	12,000	$26.41	$316,920.00	72,363
4/14/2025	Sell	12,000	$20.48	$245,760.00	77,363
2/10/2025	Sell	14,000	$19.57	$273,980.00	81,975
1/13/2025	Sell	14,000	$18.24	$255,360.00	88,975
10/15/2024	Sell	17,000	$26.87	$456,790.00	109,975
9/23/2024	Sell	17,500	$24.99	$437,325.00	116,975
8/27/2024	Sell	17,500	$26.91	$470,925.00	119,911

Eben Tessari Buying and Selling Activity at Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International Company Overview

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Today's Range

Now: $40.99

$39.79

$41.48

50 Day Range

MA: $39.46

$36.49

$42.71

2 Week Range

Now: $40.99

$17.82

$42.98

Volume

331,068 shs

Average Volume

299,683 shs

Market Capitalization

$3.11 billion

P/E Ratio

91.09

Dividend Yield

N/A

Beta

0.02

Eben Tessari Biography and Net Worth

What is Eben Tessari's net worth?

How old is Eben Tessari?

What is Eben Tessari's salary?

How do I contact Eben Tessari?

Has Eben Tessari been buying or selling shares of Kiniksa Pharmaceuticals International?

Who are Kiniksa Pharmaceuticals International's active insiders?

Are insiders buying or selling shares of Kiniksa Pharmaceuticals International?